SPARC enters into agreement for SCD-153 with JHU and IOCB

02 Nov 2023 Evaluate

Sun Pharma Advanced Research Company (SPARC) has entered into an agreement with Johns Hopkins University (JHU) and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) (Licensors) to exclusively license SCD-153 including all patents and patent applications owned or controlled by licensors.

SPARC had evaluated SCD-153 under a Material Transfer Agreement (MTA) after which it entered into an Option to License Agreement with the licensors. SPARC’s IND was approved by Drug Controller General of India (DCGI). Under the terms of the agreement, the licensors are eligible for upfront payment, milestone payments contingent upon the achievement of regulatory and sales milestones, as well as tiered royalties on sales.

Sun Pharma Advanced Research Company (SPARC) is an international pharmaceutical company engaged in research and development of drugs and delivery systems.


Sun Pharma Adv. Res Share Price

204.40 14.00 (7.35%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 869.40
Sagility India 28.03
AGS Transact Tech 79.99
Just Dial 1073.50
Krystal Integrated 643.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.